Kenia - englanti - Pharmacy and Poisons Board

cosmos limited rangwe road; off lunga lunga road, industrial - rivaroxaban - film-coated tablet - 10mg - rivaroxaban

Kenia - englanti - Pharmacy and Poisons Board

cosmos limited rangwe road, off lunga lunga road, industrial - rivaroxaban - film-coated tablet - 15mg - rivaroxaban

Kenia - englanti - Pharmacy and Poisons Board

cosmos limited rangwe road, off lunga lunga road, industrial - rivaroxaban - film-coated tablet - 20mg - rivaroxaban

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; croscarmellose sodium; hypromellose; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; purified talc; macrogol 6000; iron oxide red - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 15 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; microcrystalline cellulose; poloxamer; croscarmellose sodium; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hypromellose; sodium lauryl sulfate; magnesium stearate; lactose monohydrate; titanium dioxide; iron oxide yellow; macrogol 6000; iron oxide red; quinoline yellow aluminium lake - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 20 mg - tablet, film coated - excipient ingredients: hypromellose; croscarmellose sodium; magnesium stearate; lactose monohydrate; microcrystalline cellulose; poloxamer; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Egypti - englanti - EDA (Egyptian Drug Authority)

el-obour modern pharmaceutical industies - suspension - 220 mg/5ml

Egypti - englanti - EDA (Egyptian Drug Authority)

el-obour modern pharmaceutical industies - capsule - 200 mg

Egypti - englanti - EDA (Egyptian Drug Authority)

sedico - granules